Clinical trials: Advanced Cancers of the Prostate
Prostate Cancer
A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
The purpose of this study is to determine the efficacy and safety of relugolix 120 milligrams (mg) orally once daily for 48 weeks on maintaining serum testosterone suppression to castrate levels (< 50 nanograms/deciliter [ng/dL])…
- Trial name
- HERO (NCT03085095)
- Testing
- Relugolix, Leuprolide Acetate
- Where
- 162 sites in United States, Australia and 20 more
- Volunteers
- 1,134 people
- Sponsor
- Myovant Sciences GmbH
Castration-resistant Prostate Cancer
Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to evaluate the effectiveness of Disitamab Vedotin in the treatment of subjects with locally advanced or metastatic castration-resistant prostate cancer.
- Trial name
- NCT06227156
- Testing
- Disitamab Vedotin Injection
- Where
- 3 sites in China
- Volunteers
- 40 people
- Sponsor
- RemeGen Co., Ltd.
Prostatic Neoplasms
Phase II Study of BI 2536 in Prostate Cancer
A study to investigate the activity of BI 2536 in Prostate Cancer
- Trial name
- NCT00706498
- Testing
- BI 2536
- Where
- 6 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Astrocytoma, Brain Cancer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers…
- Conditions
- Astrocytoma, Brain Cancer, Brain Metastases, Bladder Cancer
- Trial name
- NCT04430842
- Testing
- QBS10072S
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Quadriga Biosciences, Inc.
Renal Cell Cancer, Metastatic Castration Resistant Prostate Cancer
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system.
- Trial name
- NCT02655822
- Testing
- Ciforadenant, Ciforadenant + atezolizumab
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 502 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
The purpose of the trial is to evaluate the safety, determine the recommended Phase 2 dose (RP2D), and assess preliminary clinical activity of GEN1044 in patients with solid tumors.
- Conditions
- Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT04424641
- Testing
- GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 48 people
- Sponsor
- Genmab
Neoplasms, Neoplasm Metastasis
A Study of LY3022855 In Participants With Breast or Prostate Cancer
The main purpose of this study is to learn more about how the investigational drug, LY3022855, affects the immune system in participants with advanced breast or prostate cancer that has not responded to other treatments.
- Trial name
- NCT02265536
- Testing
- LY3022855
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Eli Lilly and Company
Breast Cancer, Prostate Cancer
A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
This is a study in participants with advanced breast, ovarian, or prostate cancer to investigate the dose, safety, pharmacokinetics, and preliminary efficacy of ipatasertib in combination with rucaparib.
- Conditions
- Breast Cancer, Prostate Cancer, Ovarian Cancer
- Trial name
- NCT03840200
- Testing
- Ipatasertib, Rucaparib
- Where
- 17 sites in United States, Australia and 3 more
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Prostatic Neoplasms
Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer
The purpose of this study is to evaluate how safe PS-341(VELCADE) is when given with Docetaxel (Taxotere) to patients with androgen-independent prostate cancer, and also to see what effects (good and bad) it has on you and on…
- Trial name
- NCT00064610
- Testing
- VELCADE TM (bortezomib) for Injection
- Where
- 4 sites in United States
- Volunteers
- 102 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.
- Conditions
- Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type, Neoplasms, Prostate, Prostate Cancer
- Trial name
- NCT04249947
- Testing
- P-PSMA-101 CAR-T cells, Rimiducid
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- Poseida Therapeutics, Inc.
Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.
- Trial name
- NCT06458712
- Testing
- DSB2455
- Where
- 21 sites in United States, France and 3 more
- Volunteers
- 180 people
- Sponsor
- Duke Street Bio Ltd
Neoplasms
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells.
- Trial name
- NCT07277270
- Testing
- GSK5764227, Bevacizumab, Fluorouracil
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 83 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer
Quality of Life of Patients With Locally Advanced and Metastatic Prostate Cancer
The purpose of this study is to evaluate possible changes in quality of life related to health (HRQL) in locally advanced and metastatic prostate cancer patients, after one year of follow-up.
- Trial name
- PROS-PROSQoLI (NCT02853409)
- Where
- 14 sites in Spain
- Volunteers
- 628 people
- Sponsor
- Ipsen
Metastatic Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer
A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy
The study consists of Phase 1a (dose escalation) and Phase 1b (dose expansion). In Phase 1a, sequential cohorts of subjects will receive escalating doses of ITC-6146RO to determine maximum tolerated dose (MTD) and/or optimal…
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Metastatic Solid Tumor
- Trial name
- NCT07423117
- Testing
- ITC-6146RO
- Volunteers
- 102 people
- Sponsor
- IntoCell, Inc
Lung Cancer, Ovarian Cancer
PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine
The objective of this Study is to collect, process, and transfer biologic samples such as blood and/or tissue biopsies to determine the concordance of detected alterations obtained through liquid biopsy analyses compared to next…
- Conditions
- Lung Cancer, Ovarian Cancer, Uterine Cancer, Colorectal Cancer
- Trial name
- PREFER (NCT05697198)
- Testing
- OmniSeq Test
- Where
- 8 sites in United States
- Volunteers
- 1,429 people
- Sponsor
- Labcorp Corporation of America Holdings, Inc
Non Small Cell Lung Cancer, Cervical Cancer
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 administered IV q3w alone and in combination with…
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer
- Trial name
- NCT04925284
- Testing
- XB002, Nivolumab, Bevacizumab
- Where
- 95 sites in United States, Australia and 7 more
- Volunteers
- 269 people
- Sponsor
- Exelixis
Metastatic Castration-resistant Prostate Cancer
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Researchers are looking for a better way to treat people who have advanced metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT06052306
- Testing
- BAY3546828
- Where
- 11 sites in Canada, Finland and 2 more
- Volunteers
- 85 people
- Sponsor
- Bayer
Tumors, Glioma
A Phase I Study of ECO-4601 in Patients With Advanced Cancer
The purpose of this study was to determine the maximum tolerated dose (MTD) and the recommended dose for future studies of ECO-4601 administered as a continuous IV infusion for 14 days with 7 days recovery (21 day cycle) in…
- Conditions
- Tumors, Glioma, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00338026
- Testing
- ECO-4601
- Where
- 2 sites in Canada
- Volunteers
- 26 people
- Sponsor
- Thallion Pharmaceuticals
Prostate Cancer
Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer
This is an open label, single-centered treatment protocol designed to monitor the safety of patients treated with a 200 mg daily dose of CASODEX.
- Trial name
- NCT00846976
- Testing
- Bicalutamide
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- AstraZeneca
Advanced Prostate Cancer, GnRH Antagonist
A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer
The purpose of this clinical trial is to test the effectiveness of a dosing regimen of Teverelix DP castration rate defined as the cumulative probability of testosterone suppression to < 0.5 ng/mL with the lower bound of the 95%…
- Trial name
- NCT07457164
- Testing
- Teverelix DP 180 mg
- Volunteers
- 40 people
- Sponsor
- Antev Ltd.